Kinase inhibitor 4 minisymposium summary

Expert Review of Anticancer Therapy

Volumn 9, Issue 7, 2009, Pages 891-894

  Dancey, Janet E ^a  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Biomakers; Kinase inhibitors; Therapeutic index

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA KINASE INHIBITOR; AZD 8055; CX 4945; ETP 45658; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GSK 461364 A; GSK 461364A; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLO LIKE KINASE; PROTEIN KINASE D; PROTEIN KINASE INHIBITOR; STAT PROTEIN; TAXANE DERIVATIVE; TEMSIROLIMUS; TKI 258; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN METASTASIS; BREAST CANCER; CANCER RESEARCH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG SCREENING; ENZYME INHIBITION; FATIGUE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL SOCIETY; MELANOMA; MISSENSE MUTATION; NAUSEA; NEUTROPENIA; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPOSIUM; THROMBOCYTOPENIA; VOMITING;

EID: 69249129086     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.09.66     Document Type: Conference Paper

References (11)

1. Katoh M. Cancer genomics and genetics of FGFR2 (review). Int. J. Oncol. 33, 233-237 (2008).
2. Kim KB, Saro J, Moschos SS et al. A Phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma. J. Clin. Oncol. 26 (2008) (Abstract 9026).
3. Shi MM, Motwani M, Wang J et al. The pharmacodynamic effect of TKI258 on plasma biomarkers of angiogenesis in patients with AML and advanced melanoma. J. Clin. Oncol. 26 (2008) (Abstract 14680).
4. Wang X, Saro J, Wei Z et al. Modelling TKI258 exposure and biomarker response in support of Phase I dosing schedule finding. J. Clin. Oncol. 26, (2008) (Abstract 14691).
5. Kitzen JJ, de Jonge MJ, Verweij J. Aurora kinase inhibitors. Crit. Rev. Oncol. Hematol. DOI: 10.1016/j.critrevonc.2009.03.009 (2009).
6. Mross K, Frost A, Steinbild S et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 26, 5511-5517 (2008).
7. Wilkinson RW, Odedra R, Heaton SP et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 13, 3682-3688 (2007).
8. Olmos D, Swanton C, de Bono J. Targeting polo-like kinase: learning too little too late? J. Clin. Oncol. 26, 5497-5499 (2008).
9. Gril B, Palmieri D, Bronder JL et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl Cancer Inst. 100, 1092-1103 (2008).
10. Lin NU, Dieras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452-1459 (2009).
11. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).